Literature DB >> 7466815

Enhanced immunogenicity of xenogenized tumor cells in rats pretreated with cyclophosphamide.

M Terishimna, N Takeichi, K Suzuki, T Itaya, E Gotohoda, H Kobayashi.   

Abstract

Immunization with xenogenized tumor cells, tumor cells infected with murine leukemia viruses, produced strong antitumor immunity. In this study, the immunogenicity of xenogenized tumor cells was compared in cyclophosphamide-treated and non-treated rats. CY treatment 3 days before immunization with xenogenized tumor cells enhanced antitumor cell-mediated immunity and antibody responses. However, CY treatment after immunization had no effect. Transfer of thymus cells form normal rats before the tumor challenge abolished the CY-induced augmenting effect. From these results, it is suggested that the elimination of precursors of suppressor T-cells by CY treatment results in enhanced immunogenicity of xenogenized tumor cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7466815     DOI: 10.1620/tjem.132.355

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  3 in total

1.  Modification of regression of virally xenogenized tumor cells by cyclophosphamide and busulfan.

Authors:  K Morikawa; J Hamada; T Itaya; M Ishikawa; N Takeichi; M Hosokawa; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

2.  The improved effects of specific active immunotherapy on a rat fibrosarcoma by antitumor drugs.

Authors:  M Komatsumoto; M Hosokawa; F Okada; T Okayasu; T Tanabe; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.

Authors:  M Hosokawa; Y Sawamura; T Morikage; F Okada; Z Y Xu; K Morikawa; K Itoh; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.